Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (379)	8/28/2001 2:35:30 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 1005

Maybe not zero confidence, but luck of the knowledge what may surface (or what may not) is contributing factor to overall luck of interest for DDDP. From last 10Q: <<We expect to recognize approximately $25 million of revenue in 2001 relating to up-front fees, research funding payments, license fees and equipment sales under existing collaborations. For 2002, our existing collaborations are expected to provide revenues of approximately $20 million relating to up-front fees, research funding payments and license fees. Not included in these estimates are potential milestone payments from existing agreements or revenues from any new collaborations. We intend to enter into additional DiscoverWorks collaborations; however, our basic business model is to focus a greater portion of our effort on internal product research and development. As a result, we expect to incur increasing operating losses over the next several years. >> Ad to this additional uncertainty from last two amendments in collaboration with BIPI and BMS, DuPont collaboration expire by 01-end. Until they can show progress for in-house programs stock may and probably will be ignored. Miljenko